Clinicians are moving toward managing mild (Grade 1) cytokine release syndrome on an outpatient basis. The most common and ...

CAR-T cell therapy offers the hope of a cure to a number of cancer patients. Yet, in spite of the great effectiveness, more attention has been paid to the toxicity of the therapy known as cytokine ...

In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.

Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of ...

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...

There's no telling where the call will come from, or when. But Randy Cron, M.D., Ph.D., professor of pediatrics and medicine at UAB, knows to expect them. "Not a week goes by when I don't get a call ...

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), treatment with fixed-duration Epkinly (epcoritamab-bysp) plus dose-attenuated Rituxan (rituximab) plus cyclophosphamide ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window While the use of ...

XmAb819 demonstrated a manageable safety profile with primarily grade 1 or 2 cytokine release syndrome and no neurotoxicity in ccRCC patients. The trial involved 69 patients, with a 25% objective ...

Cytokine release syndrome can limit aggressive RRMM treatment strategies. Jeffrey Matous, MD: We’re going to talk about hurdles giving these treatments. First, let’s talk about the timing of CRS ...

As the first clinical data become available on treating coronavirus patients with the cells, scientists are equivocal about the rationale for the intervention. The immunotherapy induces a form of cell ...